Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare to Unveil its Segment Strategy At Chicago Radiology Meeting, Investor Event

General Electric Healthcare is unveiling its vision for its future in healthcare, targeting 2015 as the bulls-eye for the realization of its vision of personalized medicine.

GE Healthcare’s go-to-market strategy is woven around the phrase “Predict, Diagnose, Inform, and Treat,” and, this week in Chicago, it will provide perhaps the most in-depth explanation on how it will integrate the tools it picked up by acquiring Amersham in April with its legacy medical systems business.

“The next 15 years will deliver fundamental changes in diagnostics that will transform healthcare through greater knowledge of disease and the individual,” Bill Castell, CEO of GE Healthcare, and vice chairman of GE, said in a statement.

GE Healthcare executives were unavailable for comment prior to press time.

The company is using this week’s meeting of the Radiological Society of North America in Chicago to showcase its portfolio of healthcare tools just seven months after the completion of its $10.3-billion acquisition of Amersham.

The company has four show areas taking up 2,500 square-feet of booth space, at apprximately $29 a square foot, as well as executive-level corporate representation gathered for a formal presentation to investors later in the week.

GE’s “2015 Future Technology Pavilion” in the McCormick Exhibition Center in Chicago displays technology ranging from systems for computed tomography, magnetic resonance imagery, nuclear medicine, ultrasound, electronic information and services, and film and image management.

On Tuesday, the company launched a high-definition magnetic-resonance system at the trade show while partner Cytogen rolled out a prostate cancer-imaging system combining its molecular imaging agent with the GE Infinia Hawkeye camera system, which uses a hybrid technology based on nuclear medicine and computed tomography.

The show is expected to draw some 60,000 attendees, and is regarded as one of the largest medical industry tradeshows.

Investor’s Presentation

On Thursday, Bill Castell, president and CEO of General Electric Healthcare, and the former chief of Amersham, will led a presentation entitled “Healthcare 2015 — A New Paradigm,” that will focus on the business unit’s personalized medicine strategy. The presentation will not be webcast, but will be available afterwards on

GE Healthcare’s vision is largely built on combining the imaging and informatics tools in its legacy GE Medical Systems unit, with the ‘omics tools and other offerings it acquired with the Amersham transaction.

“I believe as we go forward with the concept of personalized medicine, you will see a merger of the in vivo and in vitro world and the merging of MRI and information from microarrays would be a good example.Trevor Hawkins told BCW’s sister publication, BioArray News, after the acquisition of Amersham in April.

Hawkins was formerly Amersham Biosciences vice president of development, discovery systems, who in August was named president of the GE Healthcare’s new molecular diagnostics business unit.

— Mo Krochmal ([email protected])


The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.